Pancreatic Cancer Clinical Trials in Philadelphia, Pennsylvania

7 studies are recruiting for pancreatic cancer in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

   This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania

   Locations

   20 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07277413 on ClinicalTrials.gov

2. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Thomas Jefferson University, Philadelphia, Pennsylvania

   Locations

   48 in total

   Run by

   Immuneering Corporation

   See if you can join NCT07562152 on ClinicalTrials.gov

3. Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   74 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07252232 on ClinicalTrials.gov

4. DESTINY-PANTUMOUR04

   This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

   Stage

   Not phased

   Ages

   18 to 130

   Site

   Research Site, Philadelphia, Pennsylvania

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07124000 on ClinicalTrials.gov

5. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

   The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   26 in total

   Run by

   Frontier Medicines Corporation

   See if you can join NCT06244771 on ClinicalTrials.gov

6. Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

   The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT02478892 on ClinicalTrials.gov

7. Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

   Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Locations

   6 in total

   Run by

   CivaTech Oncology

   See if you can join NCT02843945 on ClinicalTrials.gov